viloxazine

Adjunctive therapy • Brands: Qelbree

Last reviewed: 2025-12-30

General information

Class: Adjunctive therapy
Common US brands: Qelbree
Therapeutic drug monitoring not routinely recommended.
Last reviewed: 2025-12-30

Dosing & forms

Forms/strengths: —
Frequency: —
Food: —
Typical range: —

Mechanism (brief)

Nonstimulant ADHD medication (viloxazine extended-release) that modulates norepinephrine signaling; carries a boxed warning for suicidal thoughts/behaviors and is a strong CYP1A2 inhibitor with clinically important drug interactions.

Metabolism & Half‑life

Metabolism: CYP2D6, UGT1A9, UGT2B15
Half‑life: Single-dose mean 7 h

Therapeutic Drug Monitoring (TDM)

Recommended: No

View labelExact

Monitoring highlights

Sources

QELBREE (viloxazine) extended-release capsules prescribing information — DailyMed (2025)
Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents — Pediatrics (2019)
Attention deficit hyperactivity disorder (NICE guideline NG87) — NICE (2018)
Comparative efficacy and tolerability of medications for ADHD (systematic review and network meta-analysis) — Lancet Psychiatry (2018)